Home > Result Summaries: Compounds > fosamprenavir > Result Summary for APV30001

Result Summary for APV30001

Result Summary

Protocol ID:	APV30001
Clinical Study ID:	APV30001
Official Title:	A Phase III, Randomized, Multicenter, Parallel, Open-Label Study to Compare the Efficacy, Safety and Tolerability of GW433908 (1400mg BID) and Nelfinavir (1250mg BID) Over 48 Weeks in Antiretroviral Therapy-Naïve HIV-1 Infected Adults
Phase:	Phase 3
Study Indications or Diseases:	Infection, Human Immunodeficiency Virus
Generic Name:	fosamprenavir
Trade/Product Name:	lexiva;lexiva
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Amalia Rodriguez-French, Jack Boghossian, Glenda E Gray, Jeffrey P Nadler, Arnaldo R Quinones, Gladys E Sepulveda, Judith M Millard, Paul G Wannamaker. The NEAT Study: A 48-Week Open-label Study to Compare the Antiviral Efficacy and Safety of GW43908 Versus Nelfinavir in Antiretroviral Therapy-naïve HIV-1-infected Patients. JAIDS 2004;35(1):22-32. Abstract: Sustained antiviral efficacy and tolerability over 96 weeks in art naive subjects: long-term follow-up on unboosted gw433908 (908) bid. J Nadlerl, A Rodriguez-French G Gray D Thorpe R Elston D Thomas 15th International AIDS Conference: The Fight Continues 7/11/2004 Bangkok; Thailand